PrecisionAge Pilot Study
Zusammenfassung der Studie
The world population is aging faster than ever before. Therefore, the goal for a modern older society like Switzerland is to increase the number of healthy years. However, today's medicine primarily focuses on the treatment of manifest diseases, which has led to an increase in life expectancy but not to a corresponding extension of the years spent in good health and functionality. How we age can be influenced by lifestyle factors such as physical activity, nutrition, mental health, and the environment. Therefore, measures targeting modifiable lifestyle factors are considered an important lever for extending healthy lifespan. We would like to test in a comprehensive clinical study whether such a multimodal, personalized lifestyle intervention, consisting of a training program (strength, endurance, and mindfulness), dietary recommendations, and supplementation with vitamin D, omega-3 fatty acids, a multivitamin preparation (Centrum Silver® Adults 50+), and the tomato extract “Fruitflow®” can improve muscle function, cognition, and immune defense, as well as slow biological aging, and whether it is well tolerated and easy to implement. To gain valuable insights regarding feasibility and acceptance by study participants, we are now conducting the PrecisionAge Pilot Study with a total of 10 participants. The results of this pilot study will significantly influence the final design of the large clinical study. Participants will be randomly assigned to an active group receiving the intervention described above and a control group. The control group will not change anything about their usual lifestyle. This pilot study lasts for all participants 2-3 weeks and includes 2 visits to the study center.
(BASEC)
Untersuchte Intervention
Multimodal lifestyle intervention consisting of a training program (strength, endurance, and mindfulness), dietary recommendations, and supplementation with vitamin D, omega-3 fatty acids, a multivitamin preparation (Centrum Silver® Adults 50+), and the tomato extract 'Fruitflow®'
(BASEC)
Untersuchte Krankheit(en)
Healthy Longevity, Prevention of Accelerated Biological Aging
(BASEC)
- Individuals aged 50-70 living in the community - Low physical activity and low vegetable and fruit consumption - Increased risk for accelerated functional and biological aging (BASEC)
Ausschlusskriterien
- Smoker - Currently taking Centrum Silver® Adults 50+ or Fruitflow® - Taking Metformin or GLP-1 or SGLT-2 inhibitors (current use or used for more than 3 months in total) (BASEC)
Studienstandort
Basel
(BASEC)
Sponsor
Universitäre Altersmedizin FELIX PLATTER, Basel
(BASEC)
Kontakt für weitere Auskünfte zur Studie
Kontaktperson Schweiz
Heike A. Bischoff-Ferrari
+41 61 326 40 22
heikeannette.bischoff-ferrari@clutterunibas.chUniversitäre Altersmedizin FELIX PLATTER, Basel
(BASEC)
Allgemeine Auskünfte
Universitre Altersmedizin Felix Platter
+41 61 326 40 22+41 61 326 45 43
ha.bischoff-ferrari@felixplatter.chmichele.mattle@felixplatter.ch(ICTRP)
Name der bewilligenden Ethikkommission (bei multizentrischen Studien nur die Leitkommission)
Ethikkommission Nordwest- und Zentralschweiz EKNZ
(BASEC)
Datum der Bewilligung durch die Ethikkommission
12.06.2026
(BASEC)
ICTRP Studien-ID
NCT07523061 (ICTRP)
Offizieller Titel (Genehmigt von der Ethikkommission)
PrecisionAge Pilot Study (BASEC)
Wissenschaftlicher Titel
PrecisionAge Pilot Study (ICTRP)
Öffentlicher Titel
PrecisionAge Pilot Study (ICTRP)
Untersuchte Krankheit(en)
Aging (ICTRP)
Untersuchte Intervention
Other: multimodal lifestyle intervention: (ICTRP)
Studientyp
Interventional (ICTRP)
Studiendesign
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Investigator, Outcomes Assessor). (ICTRP)
Ein-/Ausschlusskriterien
Inclusion Criteria:
- Community-dwelling women and men (sex) aged between 55 and 70 years
- low daily exercise (i.e. <4000 steps/day on average in the last month,
self-assessment)
- low fruit and vegetable intake (< 3 per day)
- at risk for accelerated functional and biological aging based on the following
criteria:
- overweight (BMI between 25.0 and 29.9)
- at least one of the following lab values or at least borderline blood pressure
within the mentioned range:
- HbA1c 5.7 - 6.4% (pre-diabetes)
- LDL 3.4 - 4.1 mmol L- or TG > 1.7 mmol L- (atherogenesis)
- hs-CRP 2 - 3 mg L- (low-grade inflammation)
- increase in BP or borderline BP (SBP 130 - 139 / DBP 85 - 89 mmHg)
- availability of a smartphone and agrees that it can be used to connect the activity
tracker to the internet and consent that data from the activity tracker will be
uploaded and analyzed
- Ability to communicate, read and write in German
- Dietary tolerability of a Mediterranean diet (e.g. vegetables, olive oil, white
meat, fish, plant-based proteins)
- Ability to swallow supplement capsules
Exclusion Criteria:
- current smoking or vaping (smoker = More than 100 cigarettes or vapes in a life-time
OR quitted less than 15 years ago and smoked more than 8 pack-years OR quitted less
than 10 years ago and smoked max. 8 pack-years)
- current supplementation with vitamin D and/or omega-3 and/or Fruitflow and/or
Centrum Silver Adults 50+ multivitamin and/or taking any other multi-vitamin
preparate and not willing to forgo during the trial duration
- prior (ever used for more than 3 months) or current intake/application of metformin
and/or GLP-1 and/or SGLT-2-inhibitor.
- Current or recent (previous 12 months) participation in another clinical trial, or
plans of such participation during participation in this trial
- Presence of the following diagnosed health conditions in the last 4 years:
- cancer (except non-melanoma skin cancer)
- myocardial infarction, stroke, transient ischemic attack, angina pectoris, or
coronary artery intervention
- renal impairment and/or liver disease
- relevant/severe impairment in mobility that leads to an inability to participate in
the exercise component
- major visual or hearing impairment
- other serious illness that would preclude participation in the intervention
components
- Living together with another study participant (ICTRP)
nicht verfügbar
Primäre und sekundäre Endpunkte
Feasibility: eligibility rate;Feasibility: recruitment rate;Feasibility: enrollment rate;Feasibility: Retention;Feasibility: drop-out rate;Feasibility: assessment completion rate;Feasibility: data completeness (proportion with complete primary endpoint data at Day 14);Feasibility: acceptability of study;Feasibility: willingness to participate in a longer trial;Safety/tolerability: serious adverese events;Safety/tolerability: related serious adverese events (ICTRP)
nicht verfügbar
Registrierungsdatum
nicht verfügbar
Einschluss des ersten Teilnehmers
nicht verfügbar
Sekundäre Sponsoren
nicht verfügbar
Weitere Kontakte
Heike A Bischoff-Ferrari, Prof. Dr. med., DrPHHeike A Bischoff-Ferrari, Prof. Dr. med., DrPHMichele Mattle, Dr. sc. med., ha.bischoff-ferrari@felixplatter.chmichele.mattle@felixplatter.ch, +41 61 326 40 22+41 61 326 45 43, Universitre Altersmedizin Felix Platter (ICTRP)
Sekundäre IDs
EKNZ_2026-00476 (ICTRP)
Angaben zur Verfügbarkeit von individuellen Teilnehmerdaten
nicht verfügbar
Weitere Informationen zur Studie
https://clinicaltrials.gov/study/NCT07523061 (ICTRP)
Ergebnisse der Studie
Zusammenfassung der Ergebnisse
nicht verfügbar
Link zu den Ergebnissen im Primärregister
nicht verfügbar